🔗 Share this article

As America undertakes unprecedented revisions to its vaccination guidelines, a particular individual appears somewhat surprisingly: Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by casting doubt on coronavirus vaccinations during the pandemic and has zeroed in on alleged deaths following COVID-19 vaccination in her short position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Immunization Program

Agency leaders had intended to reveal major revisions to the childhood vaccination calendar in December, synchronizing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US out of step with many the global community with insufficient data for public health gain. This reveal has been delayed until the next year.

In place of Vinay Prasad, Høeg is scheduled to address the audience at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the office this calendar year.

Consolidating Power at the Agency

Høeg's temporary position could signify a closer partnership between the pharmaceutical and vaccine branches as Høeg and Prasad consolidate power at the agency – and it suggests a renewed priority upon rolling back previously authorized vaccines at the FDA.

Høeg has frequently advocated for ending specific childhood shot schedules in the US in order to be more in line with the Danish model, a society with nationalized medicine and a citizenry roughly the size of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccines – usually the domain of Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Questions Over Background

The appointee has no obvious track record in drug development, approval processes or administrative roles, which has been typical for former directors of the CBER. She has served at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“She appears not to have the requisite experience” for running the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in running a large organization. She lacks background in drug approvals.”

Past heads of the center would “grasp regulatory frameworks and the research of medication creation”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that previous people who led CBER have had.”

This division has an vast workload at the FDA, Woodcock emphasized.

“Everybody just zeroes in on the innovative therapies, but the generic drug division authorizes a multitude of generic medications. There’s a biologic copycat branch, OTC medication office and more, and every single one must be supervised,” she explained. “The area you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a major administrative element to the position, which manages more than 5,000 personnel. “It is a enormous leadership role, if you do it right,” the former official concluded.

Official Statement and Contentious Programs

In response to concerns about Dr. Høeg's fitness for the role and whether this assignment signifies greater collaboration among agency officials on vaccines, a spokesperson stated that the “concerns are based on inaccurate premises”.

“Her experience is consistent with the responsibilities of her position,” the official stated, pointing to the period Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg takes over the agency head's controversial expedited review system, a contentious one-day therapy clearance system that apparently troubled her former heads. “How are these therapies being picked for this fast-track system? Who is making the choices?” Dr. Howard asked. “There’s a lot of secrecy occurring at the agency right now.”

In general, he said, “the agency seems to be moving towards laxer oversight of pharmaceuticals, except for shots.”

Public History on Immunizations

With vaccines, Høeg has a more established, if troubling, history, some experts have noted. She authored a research paper using unconfirmed crowd-sourced reports to assess the incidence of myocarditis after Covid immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “wish list” for the current government encompassed revising regulations for novel immunizations and ending “non-essential” immunizations, she remarked post-election on a online show. At the FDA, Dr. Høeg has according to sources proposed preventing adolescent males from getting COVID-19 vaccinations.

“She’s an thorough ideologue who begins with her conclusions and reverse-engineers to fit the science in a highly disingenuous, fraudulent way,” Howard said.

Consolidating Power and a “Revenge Tour”

Høeg joined other dissenters, {like|